{"brief_title": "Denosumab (AMG 162) in Bisphosphonate Naive Metastatic Breast Cancer", "brief_summary": "This study is to evaluate various doses and schedules for denosumab administration and characterize the safety profile in this indication.", "condition": "Bone Metastases in Subjects With Advanced Breast Cancer", "intervention_type": "Drug", "intervention_name": "IV Bisphosphonates", "description": "Commercially available intravenous (IV) bisphosphonates administered per package insert, included pamidronate, ibandronic acid, and zoledronic acid", "arm_group_label": "IV bisphosphonates every 4 weeks", "other_name": "AMG 162", "criteria": "Inclusion Criteria: - Histologically or cytologically confirmed breast adenocarcinoma - At least one bone metastasis", "gender": "Female", "minimum_age": "18 Years", "maximum_age": "N/A", "healthy_volunteers": "No", "id": "NCT00091832.xml"}